Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03122197 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of Letrozole in Recurrent Gliomas

StatusRecruiting
PhaseEarly Phase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Site contact updatedv12
  2. Primary completion date: Sep 1, 2024 to Sep 1, 2027 Completion date: Dec 2024 to Dec 2027v11 Show 1 more changeShow less
    • Completion date: Dec 2024 to Dec 2027
  3. Trial status: Active, Not Recruiting to Recruiting Primary endpoints: 1 to 2 · Enrollment target: 42 to 39 · Interventions: Letrozole Oral Tablet (Drug) to Letrozole Oral Tablet (Drug), Temozolomide (Drug) · 4 morev10 Show 7 more changesShow less
    • Primary endpoints: 1 to 2
    • Enrollment target: 42 to 39
    • Interventions: Letrozole Oral Tablet (Drug) to Letrozole Oral Tablet (Drug), Temozolomide (Drug)
    • Eligibility criteria expanded, about 295 words
    • Study description expanded, about 122 words
    • Site details revised
    • Study arms: 1 to 3

    See this version in full on ClinicalTrials.gov ↗

  4. Primary completion date: Sep 1, 2023 to Sep 1, 2024 Completion date: Dec 2023 to Dec 2024v9 Show 1 more changeShow less
    • Completion date: Dec 2023 to Dec 2024
  5. Re-verified, no change to tracked fieldsv8
Show 6 earlier versionsHide 6 earlier versions
  1. Primary completion date: Jun 2022 to Sep 1, 2023 Trial status: Recruiting to Active, Not Recruiting · Completion date: Jun 2023 to Dec 2023 · Site details revisedv7 Show 3 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Completion date: Jun 2023 to Dec 2023
    • Site details revised
  2. Primary completion date: Jun 2021 to Jun 2022 Completion date: Jun 2022 to Jun 2023v6 Show 1 more changeShow less
    • Completion date: Jun 2022 to Jun 2023
  3. Study description expanded, about 34 wordsv5 See this version in full on ClinicalTrials.gov ↗
  4. Enrollment target: 12 to 42 Primary completion date: Apr 2019 to Jun 2021 · Completion date: Jun 2019 to Jun 2022v4 Show 2 more changesShow less
    • Primary completion date: Apr 2019 to Jun 2021
    • Completion date: Jun 2019 to Jun 2022
  5. Primary completion date: Apr 14, 2018 to Apr 2019 Completion date: Apr 14, 2019 to Jun 2019v3 Show 1 more changeShow less
    • Completion date: Apr 14, 2019 to Jun 2019
  6. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1 · Start date changed from estimate of Apr 21, 2017 to May 16, 2017v2 Show 2 more changesShow less
    • Study sites: 0 to 1
    • Start date changed from estimate of Apr 21, 2017 to May 16, 2017
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to determine the ability of letrozole to penetrate the blood brain barrier and concentrate in gliomas.
Trial Details
NCT Number NCT03122197
Lead Sponsor University of Cincinnati
Conditions Brain Tumor
Enrollment 39 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov